International experience of using olaparib for metastatic castration-resistant prostate cancer: literature review

被引：0
|
作者：
Matveev, V. B. [1 ]
Khalmurzaev, O. A. [1 ]
Evsyukova, O., I [1 ]
机构：
[1] Minist Hlth Russia, NN Blokhin Natl Med Res Ctr Oncol, 24 Kashirskoe Shosse, Moscow 115478, Russia
来源：
ONKOUROLOGIYA | 2020年 / 16卷 / 04期
关键词：
prostate cancer; HRR mutations; BRCA; olaparib; DNA-REPAIR;
D O I：
10.17650/1726-9776-2020-16-4-197-206
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The following review presents a problem of metastatic castration-resistant prostate cancer and its association with germline or somatic mutations in homologous recombination repair (HRR). In 2020, olaparib was approved in the Russian Federation as a monotherapy for metastatic castration-resistant prostate cancer with germline or somatic mutations of genes involved in DNA repair by homologous recombination, after progression on therapy with new hormonal drugs. We describe a review of the main olaparib clinical trials assessing its efficacy, safety and tolerance in metastatic castration-resistant prostate cancer patients.
引用
收藏
页码：197 / 206
页数：10
相关论文
共 50 条
  • [21] Contextualizing Olaparib and Abiraterone in the Current Treatment Landscape for Metastatic Castration-resistant Prostate Cancer
    Fallara, Giuseppe
    Robesti, Daniele
    Raggi, Daniele
    Montorsi, Francesco
    Necchi, Andrea
    Cooperberg, Matthew R.
    Malavaud, Bernard
    Ploussard, Guillaume
    Martini, Alberto
    EUROPEAN UROLOGY OPEN SCIENCE, 2023, 52 : 40 - 43
  • [22] Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer
    Schweizer, Michael T.
    Gulati, Roman
    Yezefski, Todd
    Cheng, Heather H.
    Mostaghel, Elahe
    Haffner, Michael C.
    Patel, Radhika A.
    De Sarkar, Navonil
    Ha, Gavin
    Dumpit, Ruth
    Woo, Brianna
    Lin, Aaron
    Panlasigui, Patrick
    McDonald, Nerina
    Lai, Michael
    Nega, Katie
    Hammond, Jeannette
    Grivas, Petros
    Hsieh, Andrew
    Montgomery, Bruce
    Nelson, Peter S.
    Yu, Evan Y.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2023, 26 (01) : 194 - 200
  • [23] Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide
    El-Amm, Joelle
    Patel, Nihar
    Freeman, Ashley
    Aragon-Ching, Jeanny B.
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2013, 7 : 235 - 245
  • [24] Cabazitaxel schedules in metastatic castration-resistant prostate cancer: a review
    Pobel, Cedric
    Auclin, Edouard
    Procureur, Adrien
    Clement-Zhao, Alice
    Simonaggio, Audrey
    Delanoy, Nicolas
    Vano, Yann-Alexandre
    Thibault, Constance
    Oudard, Stephane
    FUTURE ONCOLOGY, 2021, 17 (01) : 91 - 102
  • [25] Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection
    LeVee, Alexis
    Lin, Ching Ying
    Posadas, Edwin
    Figlin, Robert
    Bhowmick, Neil A.
    Di Vizio, Dolores
    Ellis, Leigh
    Rosser, Charlos J.
    Freeman, Michael R.
    Theodorescu, Dan
    Freedland, Stephen J.
    Gong, Jun
    ONCOTARGETS AND THERAPY, 2021, 14 : 4819 - 4832
  • [26] Resistance to Abiraterone in Castration-resistant Prostate Cancer: A Review of the Literature
    Giacinti, Silvana
    Bassanelli, Maria
    Aschelter, Anna Maria
    Milano, Annalisa
    Roberto, Michela
    Marchetti, Paolo
    ANTICANCER RESEARCH, 2014, 34 (11) : 6265 - 6269
  • [27] Abiraterone experience in a patient with metastatic castration-resistant prostate cancer on hemodialysis
    Eryilmaz, Melek Karakurt
    Karaagac, Mustafa
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (08) : 2031 - 2034
  • [28] Biomarkers in Metastatic Castration-resistant Prostate Cancer
    Miller, K.
    AKTUELLE UROLOGIE, 2015, 46 (01) : 66 - 70
  • [29] Advances in metastatic castration-resistant prostate cancer
    Kentepozidis, Nikolaos
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2014, 34 : S108 - S108
  • [30] Rucaparib in castration-resistant, metastatic prostate cancer
    Lorenz, Judith
    AKTUELLE UROLOGIE, 2024, 55 (02) : 96 - 98
12345